This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Mediware's New Chemotherapy Software Realizes Early International Success

LENEXA, Kan., Aug. 15, 2012 (GLOBE NEWSWIRE) -- Mediware Information Systems, Inc. (Nasdaq:MEDW) today announced that the company's new chemotherapy management software has realized early success through the addition of two new contracts with prestigious hospitals in the Netherlands. The new customers include St. Antonius Hospital in Nieuwegein, and Catherina Hospital in Eindhoven. Mediware announced the acquisition of this software on April 18, 2012 from Cobbler ICT Services BV and is currently marketing the software in the Netherlands and Belgium. Mediware is also aggressively building interest for the product in the United Kingdom where the company's JAC subsidiary has a significant customer base using its medication management suite of products.

The agreement with St. Antonius represents the largest sale to date for the chemotherapy management software. The hospital, which licensed the software in July, is implementing advanced automation programs for the treatment of cancer at the 700 bed teaching facility. They plan to use the software to automate and support the data management needs for the entire care process, from electronic ordering (CPOE) to preparation and administration of the specialty drug inventories. The Mediware system also includes an integrated electronic patient record to enable doctors and nurses to monitor treatments and patient outcomes over time, as well as the ability to integrate with other key information systems to help manage these complex therapies. The contract with Catherina Hospital was completed in May.

"Oncology is one of the fastest growing areas of healthcare technology because of the extreme complexity of patient cases and an intense need for both safety and efficiency," said Thomas Mann, Mediware's president and chief executive officer. "This is an excellent example of where technology, and specifically information systems, can improve caregiver response times and positively impact patient outcomes, while still helping facilities control waste and unnecessary costs."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs